Pediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatment.
Arlette L BruijstensKatelijn M BlokJoost J F M SmoldersBeatrijs Ha WokkeRinze F NeuteboomPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2020)